Edward B. Garon, MD, MS

Edward B. Garon, MD, MS, provides an overview of some of the available treatment options for patients with EGFR-mutated lung cancer.

Anne S. Tsao, MD, and Edward B. Garon, MD, MS, conclude their discussion with a look to the future of TROP2 and associated targeted therapy approaches in non–small cell lung cancer.

Thoracic oncologists discuss the progress made and unmet needs that remain in the non–small cell lung cancer treatment space.

Medical oncologists discuss where antibody-drug conjugates fit in the overall non–small cell lung cancer treatment landscape and review the ongoing EVOKE-01 and EVOKE-03 clinical trials.

Expert perspectives on clinical trials investigating doublet and triplet therapy with datopotamab deruxtecan in patients with non–small cell lung cancer.

An overview of clinical trials investigating datopotamab derutecan in patients with non–small cell lung cancer.

Edward B. Garon, MD, MS, reviews the safety profiles of sacituzumab govitecan and datopotamab deruxtecan in patients with non–small cell lung cancer.

A brief overview of clinical trials investigating datopotamab deruxtecan in patients with non–small cell lung cancer.

Thoracic oncologists discuss the EVOKE-02 study investigating sacituzumab govitecan in combination with pembrolizumab in patients with first-line metastatic NSCLC.

Comprehensive insights on clinical trial data that have led to further development of sacituzumab govitecan for patients with non–small cell lung cancer.

Experts on non–small cell lung cancer discuss the role of antibody-drug conjugates and review their mechanism of action.

A review of preclinical studies looking at TROP2 expression in patients with non–small cell lung cancer.

Edward B. Garon, MD, MS, and Anne S. Tsao, MD, provide an overview of TROP2 as a target for patients with non–small cell lung cancer.

Expert perspectives on unmet needs in the NSCLC treatment landscape and the role of antibody-drug conjugates in addressing them.

Thoracic medical oncologists discuss the evolving role of biomarkers in the non–small cell lung cancer treatment landscape.

Anne S. Tsao, MD, and Edward B. Garon, MD, MS, introduce themselves and provide an overview of the incidence, prognosis, and treatment of non–small cell lung cancer.

In the third interview of this series, Edward B. Garon, MD, reviews the treatment landscape in non–small cell lung cancer, with a focus on immunotherapy and the recent approval of tremelimumab in combination with durvalumab and platinum-based chemotherapy.

In the third installment of this series, Edward B. Garon, MD, MS, gives a historical overview of first-line immunotherapy options for non–small cell lung cancer, discusses the recent FDA approval of durvalumab/tremelimumab in combination with platinum-based chemotherapy in the same setting, and assesses treatment and research goals in the field.

In the second installment of this series, Edward B. Garon, MD, MS, explains the rationale for using combination IO therapies alongside chemotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC), discusses key data from the POSEIDON trial presented at recent meetings, and elaborates on how these regimens may change his clinical practice.

Edward B. Garon, MD, MS, provides an overview of the phase 3 CANOPY-A study.

A lung cancer expert describes the common adverse events he sees with immunotherapy in mNSCLC, and the available management strategies.

Edward B. Garon, MD, MS, shares his biomarker testing protocols for patients with NSCLC and highlights the most important biomarkers for guiding therapy.

Dr Edward B. Garon explains the rationale for treating patients with mNSCLC with a frontline combination of chemotherapy and immune checkpoint inhibitors.

Closing the program, Edward B. Garon, MD, MS, shares his view on the implications of recent mNSCLC data in clinical practice, and the unmet needs the field must focus on in the future.

Dr Garon continues with an explanation of the updated analysis of the POSEIDON trial presented at the 2022 World Conference on Lung Cancer.

A key opinion leader reviews the study design and efficacy and safety outcomes of the POSEIDON trial investigating durvalumab + tremelimumab + chemotherapy for treatment of mNSCLC.